多路复用
多重连接依赖探针扩增
淋巴细胞白血病
白血病
癌症研究
分子生物学
生物
免疫学
遗传学
基因
外显子
作者
Anne Benard-Slagter,Ilse Zondervan,Karel de Groot,Farzaneh Ghazavi,Virinder Kaur Sarhadi,Pieter Van Vlierberghe,Barbara De Moerloose,Claire Schwab,Kim Vettenranta,Christine J. Harrison,Sakari Knuutila,Jan Schouten,Tim Lammens,Suvi Savola
标识
DOI:10.1016/j.jmoldx.2017.05.004
摘要
Recurrent and clonal genetic alterations are characteristic of different subtypes of T- and B-cell lymphoblastic leukemia (ALL), and several subtypes are strong independent predictors of clinical outcome. A next-generation sequencing–based multiplex ligation-dependent probe amplification variant (digitalMLPA) has been developed enabling simultaneous detection of copy number alterations (CNAs) of up to 1000 target sequences. This novel digitalMLPA assay was designed and optimized to detect CNAs of 56 key target genes and regions in ALL. A set of digital karyotyping probes has been included for the detection of gross ploidy changes, to determine the extent of CNAs, while also serving as reference probes for data normalization. Sixty-seven ALL patient samples (including B- and T-cell ALL), previously characterized for genetic aberrations by standard MLPA, array comparative genomic hybridization, and/or single-nucleotide polymorphism array, were analyzed single blinded using digitalMLPA. The digitalMLPA assay reliably identified whole chromosome losses and gains (including high hyperdiploidy), whole gene deletions or gains, intrachromosomal amplification of chromosome 21, fusion genes, and intragenic deletions, which were confirmed by other methods. Furthermore, subclonal alterations were reliably detected if present in at least 20% to 30% of neoplastic cells. The diagnostic sensitivity of the digitalMLPA assay was 98.9%, and the specificity was 97.8%. These results merit further consideration of digitalMLPA as a valuable alternative for genetic work-up of newly diagnosed ALL patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI